Trial · NCT02497937
Outcomes38
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
21 to 38 of 38
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| SECONDARY | Change From Baseline in Chemistry: Calcium, Chloride, Glucose, Potassium, Sodium, Urea/Blood Urea Nitrogen (BUN) | Baseline and up to Day 7 of each treatment period | All Subjects Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). | Millimoles per liter | MEAN |
| SECONDARY | Change From Baseline in Creatinine, Direct Bilirubin, Total Bilirubin, Uric Acid | Baseline and up to Day 7 of each treatment period | All Subjects Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). | Micromoles per liter | MEAN |
| SECONDARY | Change From Baseline in Digoxin Level | Baseline and up to Day 7 in each treatment period | All Subjects Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). | Nanomoles per liter | MEAN |
| SECONDARY | Change From Baseline in Troponin I Levels and Type I Collagen Cross-linked C-telopeptide | Baseline and up to Day 7 in each treatment period | All Subjects Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). | Microgram per liter | MEAN |
| SECONDARY | Change From Baseline in Chemistry: N-terminal Pro-Brain Natriuretic Peptide | Baseline and up to Day 7 in each treatment period | All Subjects Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). | Nanograms per liter | MEAN |
| SECONDARY | Change From Baseline in Hematology: Basophils, Eosinophils, Lymphocytes, Monocytes, Platelet Count, White Blood Cell (WBC) Count, Total Neutrophils | Baseline and up to Day 7 in each treatment period | All Subjects Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). | Giga cells per liter | MEAN |
| SECONDARY | Change From Baseline in Hematocrit | Baseline and up to Day 7 in each treatment period | All Subjects Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). | Proportion of red blood cells in blood | MEAN |
| SECONDARY | Change From Baseline in Hemoglobin | Baseline and up to Day 7 in each treatment period | All Subjects Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). | Gram per liter | MEAN |
| SECONDARY | Change From Baseline in Mean Corpuscle Volume | Baseline and up to Day 7 in each treatment period | All Subjects Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). | Femtoliters | MEAN |
| SECONDARY | Change From Baseline in Red Blood Cell Count (RBC) and Reticulocytes | Baseline and up to Day 7 in each treatment period | All Subjects Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). | Trillion cells per liter | MEAN |
| SECONDARY | Change From Baseline in Mean Corpuscle Hemoglobin Concentration | Baseline and up to Day 7 in each treatment period | All Subjects Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). | grams per liter | MEAN |
| SECONDARY | Change From Baseline in Mean Corpuscle Hemoglobin | Baseline and up to Day 7 in each treatment period | All Subjects Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). | Picograms | MEAN |
| SECONDARY | Number of Participants With All Adverse Events (AE) and Serious Adverse Events (SAE) | Up to Day 46 | All Subjects Population. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Change From Baseline in Participant Reported Health Status (SF-36) Acute Score | Baseline and Day 7 of each treatment period | Analysis Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). | Score on a scale | MEAN |
| SECONDARY | Area Under the Concentration Time Curve (AUC) Time Zero to the Last Time of the Last Quantifiable Concentration (AUC(0-t)), AUC Over the Dosing Interval After First and Last Dose (AUC(0-tau)) and AUCall for GSK2798745 | Day 1 (Pre-dose, 0.5, 1, 1.5, 2, 3, 5, 8 and 12 hours post-dose), Day 2 (pre-dose, 12 hours post-dose), Days 3 to 6 (pre-dose), Day 7 (Pre-dose, 0.5, 1, 1.5, 2, 3, 5, 10, 24 and 48 hours post-dose) | PK Parameter Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). | hour*nanogram per mL | GEOMETRIC_MEAN |
| SECONDARY | Maximum Drug Concentration (Cmax) for GSK2798745 | Day 1 (Pre-dose, 0.5, 1, 1.5, 2, 3, 5, 8 and 12 hours post-dose), Day 2 (pre-dose, 12 hours post-dose), Days 3 to 6 (pre-dose), Day 7 (Pre-dose, 0.5, 1, 1.5, 2, 3, 5, 10, 24 and 48 hours post-dose) | PK Parameter. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). | Nanograms per milliliter | GEOMETRIC_MEAN |
| SECONDARY | Time to Maximum Observed Plasma Concentration (Tmax) for GSK2798745 | Day 1 (Pre-dose, 0.5, 1, 1.5, 2, 3, 5, 8 and 12 hours post-dose), Day 2 (pre-dose, 12 hours post-dose), Days 3 to 6 (pre-dose), Day 7 (Pre-dose, 0.5, 1, 1.5, 2, 3, 5, 10, 24 and 48 hours post-dose) | PK Parameter population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). | Hour | MEDIAN |
| SECONDARY | Elimination Half Life (T½) for GSK2798745 | Day 1 (Pre-dose, 0.5, 1, 1.5, 2, 3, 5, 8 and 12 hours post-dose), Day 2 (pre-dose, 12 hours post-dose), Days 3 to 6 (pre-dose), Day 7 (Pre-dose, 0.5, 1, 1.5, 2, 3, 5, 10, 24 and 48 hours post-dose) | PK Parameter Population. Data is not available for t1/2. The analysis was planned but not performed. PK sampling scheme was not adequate enough to reliably estimate the t1/2 of GSK2798745. |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02497937/outcomes?page=2